Latest Articles

Publication Date
All News Scientific
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Read Full Article
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - The AI Journal

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement The AI Journal

Published: Feb. 18, 2026, 1:25 p.m.
Read Full Article
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - Business Wire

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement Business Wire

Published: Feb. 18, 2026, 1 p.m.
Read Full Article
Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView

Karyopharm Therapeutics Inc. SEC 10-K Report TradingView

Published: Feb. 13, 2026, 11:05 a.m.
Read Full Article
Glycomic Insights in Gynecological Disease: From Molecular Mechanisms to Precision Diagnostics and Therapeutics.

Gynecological diseases-encompassing polycystic ovary syndrome, endometriosis, infertility, and malignancies-represent a significant global health burden affecting women's quality of life, reproductive capacity, and long-term health outcomes. While traditional diagnostics rely on …

Published: Feb. 3, 2026, midnight
Read Full Article
biomarkers glycomics gynecological cancer molecular diagnostics post-translational modifications precision medicine women’s health
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - The Manila Times

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan The Manila Times

Published: Jan. 29, 2026, 1:43 p.m.
Read Full Article
Aprea Therapeutics Reports Early Clinical Activity of APR-1051 in Advanced Endometrial Cancer with Significant Tumor Reduction - Quiver Quantitative

Aprea Therapeutics Reports Early Clinical Activity of APR-1051 in Advanced Endometrial Cancer with Significant Tumor Reduction Quiver Quantitative

Published: Jan. 29, 2026, 1:31 p.m.
Read Full Article
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - The Manila Times

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress The Manila Times

Published: Jan. 23, 2026, 1:20 p.m.
Read Full Article
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - manilatimes.net

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress manilatimes.net

Published: Jan. 23, 2026, 1:20 p.m.
Read Full Article
Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com - Investing.com Nigeria

Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com Investing.com Nigeria

Published: Jan. 16, 2026, 3:14 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!